2017 was a productive year for the MPP as it continued to play a strong role in improving access to HIV, hepatitis C and tuberculosis treatments for people living in resource-limited settings. Read our 2017 Annual Report: "Partnering for Development and Delivery".
The MPP’s patents and licences database, MedsPaL, is an information resource that provides information on the intellectual property status of selected HIV, hepatitis C, tuberculosis and other patented essential medicines in low- and middle-income countries.
Strategy and Related Feasibility Study Call for the Expansion of the MPP’s Mandate to Patented Medicines on the World Health Organization’s Model List of Essential Medicines
Geneva, 24 May 2018 — The Medicines Patent Pool Foundation (MPP) released its five-year strategic plan during a side event at the 71st World Health Assembly this evening. The strategy calls for renewed efforts to reach people living with HIV, hepatitis C and tuberculosis in low- and middle-income countries (LMICs) with better-adapted, affordable medicines.
Based on a feasibility study also presented at the MPP-partner event, The Path to Universal Health Coverage: Access to Affordable Treatments, the plan supports the expansion of the MPP model to other patented medicines with high medical value, starting with small molecules on the World Health Organization Model List of Essential Medicines (EML).
“Over the past eight years, the MPP has made significant inroads in supporting the scale-up of new antiretrovirals, as well as curative...
Twenty-five product developers now working with the MPP to manufacture low-cost, quality-assured treatments for developing countries
Geneva, 02 May 2018 — The Medicines Patent Pool (MPP) today announced five new generic manufacturing partners including the first companies from South Africa and South Korea to sign sublicensing agreements with the organisation. Adcock Ingram (Johannesburg) and Celltrion, Inc. (Incheon), along with Langhua Pharma from China, and Mangalam Drugs & Organics Limited and Arene Lifesciences Ltd. from India, join 20 other product developers working with the MPP to manufacture low-cost medicines for developing countries.
“We are pleased to expand our generic manufacturing network to 25 product developers from across the globe,” said Marie-Paule Kieny, Chair of MPP’s Governance Board. “Our increasing list of suppliers is contributing to the MPP’s overall mission to rapidly improve access to innovative treatments in low- and middle-income countries.”
The five new sublicensees...
Former President of the World Hepatitis Alliance brings two decades of experience in public health, patient advocacy and coalition-building to the organisation
Geneva, 19 April 2018 — The Medicines Patent Pool (MPP) Governance Board today announced the appointment of Charles Gore, founder and former President of the World Hepatitis Alliance, as new MPP Executive Director. Mr. Gore succeeds Greg Perry, Executive Director of the organisation from 2013-2017.
Mr. Gore brings to the MPP two decades of work as an advocate for hepatitis C patients and better treatment alternatives. He established the World Hepatitis Alliance in 2007 to raise awareness of viral hepatitis and, under his leadership, it worked with key countries on three World Health Assembly resolutions, culminating in the global agreement to eliminate viral hepatitis by 2030. The World Hepatitis Alliance has become the largest membership-based hepatitis patient group globally, with 250 member patient organisations from more than 90 nations. Mr....
“Successful cooperation of the Ministry of Health of Belarus with the Medicines Patent Pool is crucial in light of our current work to achieve the “90-90-90” goals and put an end to the epidemic in the country which is only possible when access to affordabl...”
Unable to load twitter timeline, please allow cookie